Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Strata Critical Medical, Inc.NASDAQ: SRTA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $5.46M, compared with -$1.81M a year earlier. Trailing-twelve-month EBITDA was -$6.82M.
Context
- EBITDA amounted to 6.7% of revenue in FY2025, down 2.0 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $2.18M (+116.6%) for the fiscal year ending Dec 2026, a step up from the +39.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.46M+329.5% QoQ
- Last fiscal yearDec 2025
- -$13.17M+39.0% YoY
- LTMMar 2026
- -$6.82M+67.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +401.3% | +446.8% | +45.6 pp |
| 1 year | +39.0% | +116.6% | +77.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (13.17M) USD
- Year-over-year change
- +39.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.17M) | +39.0% |
| FY2024 | 2024-12-31 | (21.6M) | +57.2% |
| FY2023 | 2023-12-31 | (50.43M) | -126.1% |
| FY2022 | 2022-12-31 | (22.31M) | +48.2% |
| FY2021 | 2021-09-30 | (43.1M) | — |
EBITDA vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +67.1% is the 4th highest of 10, against a peer median of +60.4%.
- EBITDA amounts to 2.7% of revenue for SRTA, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $81.29M USD | -72.0% | -35.9% | 5.3% | |
| LTM Feb 2026 | $75.72M USD | +10.6% | -0.8% | 19.3% | |
| LTM Mar 2026 | $63.96M USD | +156.1% | -53.4% | 14.3% | |
| LTM Mar 2026 | $52.62M USD | -25.5% | -25.5% | 4.0% | |
| LTM Mar 2026 | $38.14M USD | +9.9% | +56.4% | 4.3% | |
| LTM Mar 2026 | $8.74M USD | +489.7% | — | 9.9% | |
| LTM Mar 2026 | -$4.62M USD | +60.4% | — | 0.5% | |
| LTM Mar 2026 | -$6.31M USD | +90.7% | — | 3.5% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | -$6.82M USD | +67.1% | — | 2.7% |
| LTM Mar 2026 | -$14.81M USD | +65.1% | — | 3.9% | |
| LTM Mar 2026 | -£325.37M GBP | — | — | — | |
| Peer median (excluding SRTA) | — | +60.4% | -25.5% | 4.3% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M |
| Cost of Revenue | 40.01M | 123.85M | 183.06M | 189.77M | 158.82M |
| Gross Profit | 10.52M | 22.28M | 42.12M | 58.92M | 38.33M |
| Gross Margin | 20.8% | 15.2% | 18.7% | 23.7% | 19.4% |
| Research & Development | 1.68M | 5.55M | 4.63M | 3.18M | 3.05M |
| Selling, General & Admin | 32.93M | 70.26M | 105.61M | 89.66M | 45.08M |
| Operating Expenses | 34.61M | 75.8M | 110.24M | 92.85M | 48.13M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 6.9M |
| EBITDA | (43.1M) | (22.31M) | (50.43M) | (21.6M) | (13.17M) |
| EBITDA Margin | -85.3% | -15.3% | -22.4% | -8.7% | -6.7% |
| Operating Income | (24.09M) | (53.53M) | (68.12M) | (33.93M) | (9.81M) |
| Operating Margin | -47.7% | -36.6% | -30.3% | -13.6% | -5.0% |
| Interest Income | 460K | 3.43M | 8.44M | 7.21M | 4.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (19.6M) | 25.5M | 10.58M | 6.36M | (10.26M) |
| Income Before Tax | (43.7M) | (28.03M) | (57.54M) | (27.56M) | (20.07M) |
| Pre-Tax Margin | -86.5% | -19.2% | -25.6% | -11.1% | -10.2% |
| Income Tax Expense | (3.64M) | (772K) | (1.47M) | (255K) | 0 |
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | (15.65M) |
| Net Margin | -79.3% | -18.7% | -24.9% | -11.0% | -7.9% |
| EPS (Basic) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| EPS (Diluted) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| Weighted Avg Shares | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
| Weighted Avg Shares (Diluted) | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.